These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1799 related items for PubMed ID: 27847302

  • 1. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH.
    Cancer Lett; 2017 Feb 01; 386():47-56. PubMed ID: 27847302
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, Li Y, Bao X, Fu H, Lou L.
    Cancer Sci; 2019 Mar 01; 110(3):1064-1075. PubMed ID: 30663191
    [Abstract] [Full Text] [Related]

  • 3. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
    Chen WH, Song SS, Qi MH, Huan XJ, Wang YQ, Jiang H, Ding J, Ren GB, Miao ZH, Li J.
    Acta Pharmacol Sin; 2017 Nov 01; 38(11):1521-1532. PubMed ID: 28770827
    [Abstract] [Full Text] [Related]

  • 4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.
    Breast Cancer Res; 2015 Mar 07; 17():33. PubMed ID: 25888415
    [Abstract] [Full Text] [Related]

  • 5. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W, Guo N, Qi M, Dai H, Hong M, Guan L, Huan X, Song S, He J, Wang Y, Xi Y, Yang X, Shen Y, Su Y, Sun Y, Gao Y, Chen Y, Ding J, Tang Y, Ren G, Miao Z, Li J.
    Eur J Med Chem; 2017 Sep 29; 138():514-531. PubMed ID: 28692916
    [Abstract] [Full Text] [Related]

  • 6. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V, Illuzzi G, Héberlé E, Dantzer F.
    Bull Cancer; 2015 Oct 29; 102(10):863-73. PubMed ID: 26384693
    [Abstract] [Full Text] [Related]

  • 7. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.
    Biomed Pharmacother; 2018 Mar 29; 99():543-551. PubMed ID: 29902865
    [Abstract] [Full Text] [Related]

  • 8. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.
    Eur J Cancer; 2014 Oct 29; 50(15):2725-34. PubMed ID: 25128455
    [Abstract] [Full Text] [Related]

  • 9. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC.
    Nat Med; 2016 Feb 29; 22(2):194-201. PubMed ID: 26779812
    [Abstract] [Full Text] [Related]

  • 10. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X, Dang C, Min W, Diao Y, Hui W, Wang X, Dai Z, Wang X, Kang H.
    Breast Cancer Res Treat; 2019 Jul 29; 176(1):109-117. PubMed ID: 30989461
    [Abstract] [Full Text] [Related]

  • 11. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W, Duan B, Zeng L.
    Zhongguo Fei Ai Za Zhi; 2016 Jan 29; 19(1):16-23. PubMed ID: 26805733
    [Abstract] [Full Text] [Related]

  • 12. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q, Ji M, Zhou J, Jin J, Xue N, Chen J, Xu B, Chen X.
    Biochem Pharmacol; 2016 May 01; 107():29-40. PubMed ID: 26920250
    [Abstract] [Full Text] [Related]

  • 13. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, Gao J, Shen L.
    J Exp Clin Cancer Res; 2018 Jun 28; 37(1):129. PubMed ID: 29954437
    [Abstract] [Full Text] [Related]

  • 14. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
    Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD.
    Gynecol Oncol; 2019 Oct 28; 155(1):144-150. PubMed ID: 31434613
    [Abstract] [Full Text] [Related]

  • 15. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
    Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA.
    Mol Cancer Ther; 2021 Feb 28; 20(2):263-273. PubMed ID: 33268569
    [Abstract] [Full Text] [Related]

  • 16. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Yang ZM, Liao XM, Chen Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Ding J, Zhang A, He JX, Miao ZH.
    Acta Pharmacol Sin; 2017 Jul 28; 38(7):1038-1047. PubMed ID: 28414200
    [Abstract] [Full Text] [Related]

  • 17. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, Sonoo H.
    Breast Cancer; 2014 Jan 28; 21(1):75-85. PubMed ID: 22454224
    [Abstract] [Full Text] [Related]

  • 18. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
    Herencia-Ropero A, Llop-Guevara A, Staniszewska AD, Domènech-Vivó J, García-Galea E, Moles-Fernández A, Pedretti F, Domènech H, Rodríguez O, Guzmán M, Arenas EJ, Verdaguer H, Calero-Nieto FJ, Talbot S, Tobalina L, Leo E, Lau A, Nuciforo P, Dienstmann R, Macarulla T, Arribas J, Díez O, Gutiérrez-Enríquez S, Forment JV, O'Connor MJ, Albertella M, Balmaña J, Serra V.
    Genome Med; 2024 Aug 26; 16(1):107. PubMed ID: 39187844
    [Abstract] [Full Text] [Related]

  • 19. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Piao J, Takai S, Kamiya T, Inukai T, Sugita K, Ohyashiki K, Delia D, Masutani M, Mizutani S, Takagi M.
    Cancer Lett; 2017 Feb 01; 386():131-140. PubMed ID: 27894958
    [Abstract] [Full Text] [Related]

  • 20. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
    Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T.
    Oncotarget; 2016 Nov 15; 7(46):75551-75560. PubMed ID: 27705909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.